Dendritic cell vaccine therapy for colorectal cancer
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2020-12-28 / Pharmacol Res 2021 Feb;164:105374Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice
/in Colorectal Cancer, International Publications, Newcastle Disease Virus /von 2020-12-08 / PeerJ 2020;8:e9761The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2020-08-13 / Immunotherapy 2020 Aug;Cytotoxicity study of the interleukin-12-expressing recombinant Newcastle disease virus strain, rAF-IL12, towards CT26 colon cancer cells in vitro and in vivo
/in Colorectal Cancer, International Publications, Newcastle Disease Virus /von 2020-06-29 / Cancer Cell Int. 2020;20:278Dendritic Cell-Based Therapy Using LY6E Peptide with a Putative Role Against Colorectal Cancer
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2020-05-22 / Immunotargets Ther 2020;9:95-104Feasibility of modulated electro-hyperthermia in preoperative treatment for locally advanced rectal cancer: Early phase 2 clinical results
/in Colorectal Cancer, Hyperthermia, International Publications /von 2020-02-09 / Neoplasma 2020 May;67(3):677-683Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2019-10-03 / Cancers (Basel) 2019 Oct;11(10)Application of Newcastle disease virus in the treatment of colorectal cancer
/in Colorectal Cancer, International Publications, Newcastle Disease Virus /von 2019-08-26 / World J Clin Cases 2019 Aug;7(16):2143-2154Modulated electro-hyperthermia induced p53 driven apoptosis and cell cycle arrest additively support doxorubicin chemotherapy of colorectal cancer in vitro
/in Colorectal Cancer, Hyperthermia, International Publications /von 2019-06-10 / Cancer Med 2019 Jun;IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de